Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)

NCT05577754 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)

Interventions

DRUG: Alpelisib (BYL719)
DRUG: Matching placebo
PROCEDURE: Optional lumbar puncture + blood sample

Sponsor

Centre Hospitalier Universitaire Dijon

Collaborators

[object Object]